Stocksigma LogoStocksigma Logo

Novyra Pharmachem Reports Q2 Results with Widening Net Loss Despite Revenue Surge

Novyra Pharmachem reported total revenue of ₹426.78 lakh for the quarter ended 30th Sep'26, jumping sharply from ₹3.31 lakh YoY and ₹172.61 lakh QoQ

Novyra Pharmachem Reports Q2 Results with Widening Net Loss Despite Revenue Surge

Bansisons Tea Industries Ltd · Financial Result · 02 Nov 2026, 11:21 pm

Novyra Pharmachem Reports Q2 Results with Widening Net Loss Despite Revenue Surge Novyra Pharmachem reported total revenue of ₹426.78 lakh for the quarter ended 30th Sep'26, jumping sharply from ₹3.31 lakh YoY and ₹172.61 lakh QoQ, driven primarily by ₹423.08 lakh from its Pharma segment. Despite top-line expansion, total expenses rose to ₹430.10 lakh due to ₹414.02 lakh in stock purchases, leading to a net loss of ₹3.32 lakh compared to a profit of ₹0.10 lakh YoY and a loss of ₹1.99 lakh QoQ. Diluted EPS stood at ₹(0.05).

Original exchange filing (PDF)

More announcements from Bansisons Tea Industries Ltd

All Bansisons Tea Industries Ltd announcements